Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”This weekend I attended the 2026 Thrombosis and Hemostasis Summit of North America alongside many dedicated colleagues from our Rare Disease team.
I left feeling inspired by the collaboration and expertise that went into making this meeting such a valuable experience.
It was energizing to connect with the thrombosis and hemostasis community, sharing scientific perspectives and how we’re working to shape the future of care for people living with hemophilia.
From scientific presentations to educational symposia, our presence reflected a continued focus on innovation and progress for the rare bleeding disorders community.
THSNA reinforced the power of fueling conversations, sharing insights, and learning together matters as we work to accelerate progress in this area of unmet need.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 15:27Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
-
Mar 26, 2026, 15:19Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
-
Mar 26, 2026, 15:19Attilio Cotroneo: Updated Evidence-Based Recommendations for the Management of BTAI
-
Mar 26, 2026, 15:14Rodrigo Assar: Thrombosis Risk Prediction in Pediatric Central Lines
-
Mar 26, 2026, 14:48Alfonso J. Tafur: We Need to Rethink What Drives Disparities in Blood Clot Outcomes
-
Mar 25, 2026, 16:00Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
-
Mar 25, 2026, 15:56Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
-
Mar 25, 2026, 15:52Indunil Karunarathna: Kawasaki Disease at the Intersection of Immunology, Cardiology, and Vascular Biology
-
Mar 25, 2026, 15:48Micah Grey: Reflecting on an Incredible Experience at the THSNA Congress